{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:01:36Z","timestamp":1782554496708,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ajoc.2023.101979","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T16:42:43Z","timestamp":1703608963000},"page":"101979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-8575","authenticated-orcid":false,"given":"Ankur A.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4543-6081","authenticated-orcid":false,"given":"Jovana","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-1449","authenticated-orcid":false,"given":"Amar P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2023.101979_bib1","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. Available at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer. [Accessed 5 June 2022]."},{"key":"10.1016\/j.ajoc.2023.101979_bib2","series-title":"Bioconjugator. Antibody-Drug Conjugate Structure.","year":"2017"},{"issue":"10","key":"10.1016\/j.ajoc.2023.101979_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody\u2013drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.ajoc.2023.101979_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2147\/CMAR.S294080","article-title":"Therapeutic potential of tisotumab vedotin in the treatment of recurrent or metastatic cervical cancer: a short report on the emerging data","volume":"15","author":"Agostinelli","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101979_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajoc.2023.101979_bib6","series-title":"Seagen Inc. Tisotumab Vedotin-Tftv (TIVDAK). Package Insert","year":"2021"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101979_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101979_bib8","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.ajoc.2023.101979_bib9","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","article-title":"Adverse events of antibody\u2013drug conjugates on the ocular surface in cancer therapy","volume":"25","author":"Dom\u00ednguez-Llamas","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ajoc.2023.101979_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajoc.2023.101979_bib11","first-page":"63","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"Ando","year":"2011","journal-title":"Mol Vis"},{"issue":"7","key":"10.1016\/j.ajoc.2023.101979_bib12","first-page":"1359","article-title":"Ocular toxicity and cancer chemotherapy","volume":"78","author":"al-Tweigeri","year":"1996","journal-title":"A review. Cancer."},{"issue":"6","key":"10.1016\/j.ajoc.2023.101979_bib13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623001871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623001871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:28:17Z","timestamp":1721176097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993623001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":13,"alternative-id":["S2451993623001871"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101979","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101979"}}